Translational Development Acquisition (TDAC) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 0 183 sessions, October 29, 2025 to October 29, 2026
- Largest daily move
- +0.9% close of July 28, 2026
- 1-year change
- +3.8% closing prices, October 29, 2025 to October 29, 2026
- 1-month change
- -0.2% closing prices, September 29, 2026 to October 29, 2026
Company Description
Translational Development Acquisition (NASDAQ: TDAC) is classified in the shell companies industry within the Financial Services sector and carries a market capitalization of $209.5M.
TDAC has gained 3.8% over the past year. The last closing price was $10.85.
For FY2025, Translational Development Acquisition reported net income of $6.4M.
This page collects what Stock Titan holds for TDAC, including price data, latest news, SEC filings, financial highlights, and short interest trends.
Stock Performance
Translational Development Acquisition (TDAC) closed at $10.85 on October 29, 2026. Over the past 12 months, the price has gained 3.8%.
TDAC Metrics & Rankings
Price returns through October 29, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Translational Development Acquisition has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition. View all TDAC news →
SEC Filings
Translational Development Acquisition has filed 10 recent SEC filings, including 6 Form 425, 2 Form SCHEDULE 13G/A, 1 Form 10-Q, 1 Form SCHEDULE 13G. The most recent filing was submitted on October 8, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TDAC SEC filings →
Financial Highlights
operating income reached -$945K, and net income was $6.4M. The company generated -$608K in operating cash flow. The current ratio was 0.07, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Translational Development Acquisition (TDAC) currently stands at 8.6 thousand shares, down 54.5% from the previous reporting period, representing 0.0% of the float. Since October 2025, short interest has increased by 3822.5%.
Days to Cover History
Days to cover for Translational Development Acquisition (TDAC) currently stands at 1.7 days, up 56.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since October 2025, the figure has increased by 71%. Across the settlements charted above, it has ranged from 1.0 to 20.8 days.
TDAC Company Profile & Sector Positioning
Translational Development Acquisition (TDAC) operates in the Shell Companies industry within the broader Financial Services sector and is listed on the NASDAQ.
Investors comparing TDAC often look at related companies in the same sector, including Real Asset Acquisition Corp. (RAAQ), Helix Acquisition Corp. II (HLXB), Sanaby Health (SANB), Melar Acquisition Corp. I (MACI), and Larkspur Health Acquisition Corp (LSPR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TDAC's relative position within its industry.